Evaluation of Health-Related Quality-of-Life Measures in Oncology Drug Product Applications: Issues and Concerns

Journal of Biopharmaceutical Statistics

Volumn 14, Issue 1, 2004, Pages 23-30

  Sridhara, Rajeshwari ^a   Chen, Gang ^b   Chi, George Y H ^a   Griebel, Donna J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

HRQOL; Oncology drug products; Patient reported outcome

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL STUDY; EVALUATION; METHODOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG APPROVAL; HEALTH; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 1542349208     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-120028504     Document Type: Review

References (30)

1. Aaronson, N. K., Ahmedzai, S., Bergman, B. et al. (1993). The European organization for research and treatment of cancer QLQ-30, a quality-of-life instrument for use in international clinical trials in oncology. JNCI 85:365-376.
2. Baur, P. (1991). Multiple testing in clinical trials. Statist. Med. 10:871-890.
3. Cella, D. F., Tulsky, D. S., Gray, G. et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. JCO 11:570-579.
4. Cella, D., Bullinger, M., Scott, C. et al. (2002). Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin. Proc. 77:384-478.
5. DeGruttola, V., Tu, X. M. (1994). Modeling progression of CD-4 lymphocyte count and its relationship to survival time. Biometrics 50:1003-1014.
6. Fairclough, D. L., Peterson, H. F., Cella, D. et al. (1998). Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Statist. Med. 17:781-796.
7. Fairclough, D. L., Peterson, H. F., Chang, V. (1998). Why are missing quality of life data a problem in clinical trial of cancer therapy? Statist. Med. 17:667-677.
8. Frost, M. H., Bonomi, A. E., Ferrans, C. E. et al. (2002). Patient, clinician, and population perspectives on determining the clinical significance of quality of life scores. Mayo Clin. Proc. 77:488-560.
9. Guyatt, G. H., Osoba, D., Wu, A. W. et al. (2002). Methods to explain the clinical significance of health status measures. Mayo Clin. Proc. 77:371-383.
10. Hochberg, Y., Tamhane, A. C. (1987). Multiple Comparison Procedures. New York: Wiley.
11. Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scand. J. Statist. 6:65-70.
12. Hommel, G. (1988). A stagewise rejective multiple test based on a modified Bonferroni test. Biometrika 75:383-386.
13. Johnson, J., Williams, G., Pazdur, R. (2003). End points and United States Food and Drug Administration approval of oncology drugs. JCO 21:1404-1411.
14. Laird, N. M., Ware, J. H. (1982). Random-effects models for longitudinal data. Biometrics 38:963-974.
15. Levine, M. N., Ganz, P. H. (2002). Beyond the development of quality of life instruments: Where do we go from here? JCO 20:2215-2216.
16. Little, R. J. A. (1993). Pattern-mixture models for multivariate incomplete data. JASA 88:125-134.
17. Little, R. (1995). Modeling the drop-out mechanism in repeated-measures studies. JASA 90:1112-1121.
18. Rubin, D., Schenker, N. (1986). Multiple imputation for interval estimation from simple random samples with ignorable nonresponse. JASA 81:366-374.
19. Saymonds, T., Berzon, R., Marquis, P. et al. (2002). The clinical significance of quality of life results: Practical considerations for specific audiences. Mayo Clin. Proc. 77:572-583.
20. Schipper, H., Clinich, J., McMurray, A. et al. (1984). Measuring the quality of life of cancer patients: The functional living index-cancer - Development and validation. JCO 2:472-483.
21. Schluchter, M. D. (1992). Methods for the analysis of informatively censored longitudinal data. Statist. Med. 11:1861-1870.
22. Simes, R. J. (1986). An improved Bonferroni procedure for multiple tests of significance. Biometrika 73:751-754.
23. Sloan, J. A., Aaronson, N., Cappelleri, J. C. et al. (2002a). Assessing the clinical significance of single items relative to summated scores. Mayo Clin. Proc. 77:479-487.
24. Sloan, J. A., Cella, D., Frost, M. H. et al. (2002b). Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin. Proc. 77:367-370.
25. Soni, M. K., Cella, D. (2002). Quality of life and symptom measures in oncology: An overview. Am. J. Manag. Care 8:S560-573.
26. Sprangers, M. A. G., Moinpour, C. M., Moynihan, T. J. et al. (2002). Assessing meaningful change in quality of life over time: A users' guide to clinicians. Mayo Clin. Proc. 77:561-571.
27. Stone, A. A., Shiffman, S., Schwartz, J. E. et al. (2002). Patient non-compliance in paper diaries. Br. Med. J. 324:1193-1194.
28. Tannock, I. F., Osoba, D., Stockler, M. R. et al. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. JCO 14:1756-1764.
29. Westfall, P. H., Krishen, A. (2001). Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J. Statist. Plann. Inference 99:25-40.
30. Westfall, P. H., Young, S. S. (1993). Resampling Based Multiple Testing: Examples and Methods for P-value Adjustment. New York: Wiley.